Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients

被引：5

作者：

Carrato, Alfredo ^{[1
]}

Paz-Ares Rodriguez, Luis ^{[2
]}

Rodriguez Lescure, Alvaro ^{[3
]}

Casas Fernandez de Tejerina, Ana Ma ^{[2
]}

Rubio Garcia, Eduardo Diaz ^{[4
]}

Perez Segura, Pedro ^{[4
]}

Constenla Figueiras, Manuel ^{[5
]}

Garcia Carbonero, Rocio ^{[6
]}

Gomez Codina, Jose ^{[7
]}

Lluch Hernandez, Ana ^{[8
]}

Maroto Rey, Jose Pablo ^{[9
]}

Martin Jimenez, Miguel ^{[4
]}

Mayordomo Camara, Jose Ignacio ^{[10
]}

Moreno Nogueira, Jose Andres ^{[2
]}

Rueda Dominguez, Antonio ^{[11
]}

机构：

[1] Ramon y Cajal Univ Hosp, Dept Med Oncol, ES-28034 Madrid, Spain

[2] Hosp Virgen del Rocio, Seville, Spain

[3] Hosp Gen Univ Elche, Elche, Spain

[4] Hosp Clin Univ San Carlos, Madrid, Spain

[5] Complejo Hosp Pontevedra, Pontevedra, Spain

[6] Hosp Severo Ochoa, Madrid, Spain

[7] Hosp Univ La Fe, Valencia, Spain

[8] Hosp Clin Univ Valencia, Valencia, Spain

[9] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[10] Hosp Clin Univ Lozano Blesa, Zaragoza, Spain

[11] Hosp Virgen de la Victoria, Malaga, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2009年 / 11卷 / 07期

关键词：

Colony-stimulating factors; Neutropenia; Febrile neutropenia; Chemotherapy; Consensus; INDUCED FEBRILE NEUTROPENIA; SINGLE-ADMINISTRATION PEGFILGRASTIM; CHEMOTHERAPY-INDUCED NEUTROPENIA; 3-WEEKLY CHOP CHEMOTHERAPY; CELL LUNG-CANCER; BREAST-CANCER; PERIPHERAL-BLOOD; DAILY FILGRASTIM; GROWTH-FACTORS; DOUBLE-BLIND;

D O I：

10.1007/s12094-009-0383-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Neutropenia is a common complication of cancer chemotherapy. Colony-stimulating factors (CSF) may be used to avoid neutropenia-associated complications. The Spanish Society of Medical Oncology (SEOM) recently constituted a working group to review the main issues concerning the use of CSF and carried out a consensus process about the use of CSF in cancer patients, held in Madrid on 26 May 2006. The group concluded the following recommendations: prophylactic use of CSF is recommended when a rate of febrile neutropenia (FN) higher than 20% is expected without the use of CSF or when additional risk factors for neutropenia exist; therapeutic use of CSF is recommended in order to treat FN episodes but not to treat afebrile neutropenic episodes. In addition, the use of CSF is considered effective when used to mobilise stem cells before high-dose chemotherapy and when used for chemotherapy schedule optimisation in dose-dense and in dose-intense regimens.

引用

页码：446 / 454

页数：9

共 61 条

[1]

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours [J].

Aapro, M. S. ;

Cameron, D. A. ;

Pettengell, R. ;

Bohlius, J. ;

Crawford, J. ;

Ellis, M. ;

Kearney, N. ;

Lyman, G. H. ;

Tjan-Heijnen, V. C. ;

Walewski, J. ;

Weber, D. C. ;

Zielinski, C. .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (15) :2433-2453

[2]

ALMENAR D, 2005, BLOOD S, V106

[3]

Cancer and aging - An evolving panorama [J].

Balducci, L ;

Extermann, M .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2000, 14 (01) :1-+

[4]

The role of myelopoietic growth factors in managing cancer in the elderly [J].

Balducci, L ;

Carreca, I .

DRUGS, 2002, 62 (Suppl 1) :47-63

[5]

Balducci L, 2000, Oncologist, V5, P224, DOI 10.1634/theoncologist.5-3-224

[6]

Balducci Lodovico, 2003, J Support Oncol, V1, P30

[7]

Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients - A systematic review of the literature with meta-analysis [J].

Berghams, T ;

Paesmans, M ;

Lafitte, JJ ;

Mascaux, C ;

Meert, AP ;

Jacquy, C ;

Burniat, A ;

Steels, E ;

Vallot, F ;

Sculier, JP .

SUPPORTIVE CARE IN CANCER, 2002, 10 (03) :181-188

[8]

EFFICACY AND TOLERABILITY OF RECOMBINANT HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS WITH CHEMOTHERAPY-RELATED LEUKOPENIA AND FEVER [J].

BIESMA, B ;

DEVRIES, EGE ;

WILLEMSE, PHB ;

SLUITER, WJ ;

POSTMUS, PE ;

LIMBURG, PC ;

STERN, AC ;

VELLENGA, E .

EUROPEAN JOURNAL OF CANCER, 1990, 26 (09) :932-936

[9]

Protease inhibitors potentiate chemotherapy-induced neutropenia [J].

Bower, M ;

McCall-Peat, N ;

Ryan, N ;

Davies, L ;

Young, AM ;

Gupta, S ;

Nelson, M ;

Gazzard, B ;

Stebbing, J .

BLOOD, 2004, 104 (09) :2943-2946

[10]

A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma [J].

Bruns, I ;

Steidl, U ;

Kronenwett, R ;

Fenk, R ;

Graef, T ;

Rohr, UP ;

Neumann, F ;

Fischer, J ;

Scheid, C ;

Hübel, K ;

Haas, R ;

Kobbe, G .

TRANSFUSION, 2006, 46 (02) :180-185

← 1 2 3 4 5 6 7 →